Austria

Medical Only (Private)

Reimbursed Care Access

Austria maintains a restrictive controlled‑substances framework (Suchtmittelgesetz) that places classical psychedelics (psilocybin, MDMA, DMT, mescaline, 2C‑X, etc.) under criminal control with no routine medical reimbursement; exceptions exist for licensed medical uses of ketamine and for esketamine (Spravato) following EU/EMA authorization. Access to most psychedelics is limited to authorised clinical research or tightly supervised medical contexts (esketamine) or off‑label specialist use (ketamine infusions), and routine coverage by public statutory health insurance is uncommon and depends on case‑by‑case decisions. Clinical trials of psilocybin have been authorised at Austrian sites, but these represent research‑only access pathways rather than reimbursed standard care.

Read Full Access Guide View Active Trials

Clinical Trials in Austria

RecruitingPhase III

The Effect of a Four Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (INTENSIFY MDD)

Open-label, randomised, parallel trial with blinded raters (n=418) comparing early-intensified pharmacological treatment including esketamine or ketamine (twice-weekly for 4 weeks) plus a second-line antidepressant versus treatment as usual in adults (18–65) with MDD and first-line treatment failure.

Started: March 31, 2024
Type: interventional
Blinding: single
Randomized: Yes
Registry ID: NCT05973851

RecruitingPhase NA

Ketamine and Stress in OCD

Randomized, double-blind, comparator-controlled crossover trial (n=30) testing low-dose IV ketamine (0.5 mg/kg, 40 min infusion) versus midazolam in patients with OCD at the Medical University of Vienna.

Started: August 1, 2022
Type: interventional
Blinding: triple
Randomized: Yes
Registry ID: NCT05577585

RecruitingPhase I

The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects

Phase I, randomised, placebo-controlled crossover study (n=60; 25 MDD patients, 35 healthy controls) assessing IV subanaesthetic ketamine (0.5 mg/kg) vs saline during MRI to investigate effects on aesthetic processing and role in antidepressant/anhedonia mechanisms.

Started: June 1, 2022
Type: interventional
Blinding: single
Randomized: Yes
Registry ID: NCT05320107

CompletedPhase III

Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study

Randomised, double-blind, crossover Phase III pilot (n=20) comparing IV esketamine (Ketanest S) versus active placebo (diphenhydramine) for negative and depressive symptoms in patients with schizophrenia-spectrum disorders.

Started: September 7, 2021
Type: interventional
Blinding: double
Randomized: Yes
Registry ID: 2019-004489-16

WithdrawnPhase III

ECT vs. Esketamine

This longitudinal, randomized controlled trial (n=0, withdrawn) compares the efficacy of Electroconvulsive Therapy (ECT) and intranasal esketamine in patients with Treatment-Resistant Depression (TRD).

Started: July 28, 2021
Type: interventional
Blinding: none
Randomized: Yes
Registry ID: NCT04924257

Unknown statusPhase NA

Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray

This randomized, controlled pragmatic trial (n=70) assesses the value of adding edupression.com® as a therapy adjunct to esketamine nasal spray in therapy-resistant depressive (TRD) patients.

Started: April 29, 2021
Type: interventional
Blinding: single
Randomized: Yes
Registry ID: NCT04843462

Austria

Reimbursed Care Access

Clinical Trials in Austria

The Effect of a Four Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (INTENSIFY MDD)

Ketamine and Stress in OCD

The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects

Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study

ECT vs. Esketamine

Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray

Research Events

Company

Product

Legal